David Bautz, PhD retweeted
$CYCN: Engineering a Reset; Initiating Coverage of @Cyclerion Therapeutics… buff.ly/cvYjEqK by @DavidBautz
David Bautz, PhD retweeted
$ICU: Critical Care Innovation for AKI Patients; Initiating Coverage of @SeaStarMedical Holding Corp. buff.ly/McaoWX4 by @DavidBautz
. @PopTartsUS my kids opened their pop tart and it looked like this. Bruh, what happened at the manufacturing plant that day?
3
750
$NRBO IND cleared for DA-1726 for treatment of obesity; P1 trial to start 1H24. Initiation report available here: s27.q4cdn.com/906368049/file…
2
624
David Bautz, PhD retweeted
$ABEO: Initiating Coverage Of @AbeonaBio; Using Gene Therapy To Treat Orphan Diseases… - https://nitter.cf/t.co/ozxKSVTx97 by @DavidBautz
David Bautz, PhD retweeted
$EPIX: @EssaPharma Deep And Sustained PSA Responses In Phase 1/2 Combination Trial Of EPI-7386 And Enzalutamide… - https://nitter.cf/t.co/CNPxeEk3af by @DavidBautz
David Bautz, PhD retweeted
$MDNA: @Medicenna1 ABILITY Study Advancing To Sixth Dosing Cohort… - https://nitter.cf/t.co/FOpUOZfp8U by @DavidBautz
David Bautz, PhD retweeted
$KMDA: Initiating Coverage On Kamada Ltd; A Commercial Stage Biopharmaceutical Company With A Portfolio Of Marketed Products… - https://nitter.cf/t.co/Hj7hS5qsW3 by @DavidBautz
David Bautz, PhD retweeted
$BTAI: @BioXcel_Tx Multiple Catalysts Ahead in 2023 - https://nitter.cf/t.co/qvZPCf8Mnp by @DavidBautz
David Bautz, PhD retweeted
$EDSA: @EdesaBiotech 1.0% EB01 Cream Achieves Primary Endpoint In Phase 2b Trial… - https://nitter.cf/t.co/N7HCaFgKSr by @DavidBautz
David Bautz, PhD retweeted
$ARWR: @ArrowheadPharma Encouraging Results For Phase 2 SEQUOIA Trial… - https://nitter.cf/t.co/cKV8OHOLX3 by @DavidBautz
Looking to treat #DMD and other muscular dystrophies with small molecule therapies
$MSCLF: @SatellosBio Initiating Coverage Of Satellos Biosciences; A Muscle Regeneration Company… - https://nitter.cf/t.co/0HHGERVtzf by @DavidBautz
David Bautz, PhD retweeted
$MDNA: @Medicenna1 Confirmed Partial Response In Pancreatic Cancer Patient… - https://nitter.cf/t.co/eLos8R8Xey by @DavidBautz
David Bautz, PhD retweeted
$EDSA: @EdesaBiotech Statistically Significant Mortality Reduction In Phase 2 ARDS Trial… - https://nitter.cf/t.co/U2UaWSTP4N by @DavidBautz
David Bautz, PhD retweeted
$BVXV: @BiondVax Results For Preclinical Inhalation Proof-Of-Concept Study In COVID-19 Expected By End Of This Year…
- https://nitter.cf/t.co/mYekazkAfL by @DavidBautz
David Bautz, PhD retweeted
We are pleased to announce the peer reviewed publication of results from the #NurOwn® Phase 2 progressive multiple sclerosis (PMS) trial in @MSJ_Research: 🧵
ir.brainstorm-cell.com/2022-…
David Bautz, PhD retweeted
$APLIF $APLI: @Appili Advancing Multiple Programs To Combat Infectious Diseases… - https://nitter.cf/t.co/rFiw1K8Z0D by @DavidBautz























